Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Watanabe

Showing results (741-750 of 817) with videos related to

Pageof 82
Sort By:
Translational Lung Cancer Research|August 25, 2021
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)Hibiki Udagawa, Eri Sugiyama, Toshiyuki Harada, et al.
Artificial Organs|October 25, 2021
Outcomes after extracorporeal membrane oxygenation support in COVID-19 and non-COVID-19 patientsChitaru Kurihara, Adwaiy Manerikar, Catherine Aiyuan Gao, et al.
Translational Lung Cancer Research|August 12, 2022
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)Satoshi Shoji, Satoru Miura, Satoshi Watanabe, et al.
Cancer Immunology, Immunotherapy : CII|October 17, 2021
PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transferMiho Takahashi, Satoshi Watanabe, Ryo Suzuki, et al.
Scientific Reports|November 21, 2019
Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasisSatoshi Nakano, Shuhei Osaka, Yusuke Sabu, et al.
Japanese Journal of Clinical Oncology|January 25, 2024
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING studyHisao Imai, Takashi Kijima, Koichi Azuma, et al.
Translational Lung Cancer Research|August 25, 2021
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapyXuanye Zhang, Dan Tian, Yue Chen, et al.
Communications Biology|September 25, 2025
Elucidation of the structure and molecular mechanisms of the aspartate antiporterKei Nanatani, Lan Guan, Ryo Kanno, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2025
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysisToshiya Fujisaki, Eisaku Miyauchi, Gen Kida, et al.
Iscience|March 5, 2024
Discovery of non-genomic drivers of YAP signaling modulating the cell plasticity in CRC tumor linesNobuhiko Ogasawara, Yoshihito Kano, Yosuke Yoneyama, et al.
Pageof 82

Showing results (741-750 of 817) with videos related to

Sort By:
Pageof 82
Translational Lung Cancer Research|August 25, 2021
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)Hibiki Udagawa, Eri Sugiyama, Toshiyuki Harada, et al.
Artificial Organs|October 25, 2021
Outcomes after extracorporeal membrane oxygenation support in COVID-19 and non-COVID-19 patientsChitaru Kurihara, Adwaiy Manerikar, Catherine Aiyuan Gao, et al.
Translational Lung Cancer Research|August 12, 2022
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)Satoshi Shoji, Satoru Miura, Satoshi Watanabe, et al.
Cancer Immunology, Immunotherapy : CII|October 17, 2021
PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transferMiho Takahashi, Satoshi Watanabe, Ryo Suzuki, et al.
Scientific Reports|November 21, 2019
Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasisSatoshi Nakano, Shuhei Osaka, Yusuke Sabu, et al.
Japanese Journal of Clinical Oncology|January 25, 2024
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING studyHisao Imai, Takashi Kijima, Koichi Azuma, et al.
Translational Lung Cancer Research|August 25, 2021
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapyXuanye Zhang, Dan Tian, Yue Chen, et al.
Communications Biology|September 25, 2025
Elucidation of the structure and molecular mechanisms of the aspartate antiporterKei Nanatani, Lan Guan, Ryo Kanno, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2025
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysisToshiya Fujisaki, Eisaku Miyauchi, Gen Kida, et al.
Iscience|March 5, 2024
Discovery of non-genomic drivers of YAP signaling modulating the cell plasticity in CRC tumor linesNobuhiko Ogasawara, Yoshihito Kano, Yosuke Yoneyama, et al.
Pageof 82